Schrodinger Inc
Suletud
SektorTervishoid
14.36 -9.06
Ülevaade
Aktsiahinna muutus
24h
Min
14.18
Max
15.78
Sissetulek | -196M -60M |
|---|---|
Müük | -29M 59M |
Aktsiakasum | -0.62 |
Kasumimarginaal | -102.456 |
Töötajad | 850 |
EBITDA | -85M -49M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +18.61% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 217M 1.2B |
|---|---|
Eelmine avamishind | 23.42 |
Eelmine sulgemishind | 14.36 |
Schrodinger Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Schrodinger Inc Prognoos
Hinnasiht
By TipRanks
18.61% tõus
12 kuu keskmine prognoos
Keskmine 18.8 USD 18.61%
Kõrge 24 USD
Madal 13 USD
Põhineb 7 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
